DPYD Inhibitors

DPYD inhibitors belong to a class of small-molecule compounds designed to selectively target dihydropyrimidine dehydrogenase (DPD), an essential enzyme involved in the catabolism of pyrimidine bases, including uracil and thymine. DPD plays a crucial role in the metabolism of certain drugs, notably fluoropyrimidines like 5-fluorouracil (5-FU). Inhibitors of DPD have been developed to modulate its enzymatic activity, influencing the pharmacokinetics and bioavailability of fluoropyrimidine drugs. By targeting DPD, these inhibitors aim to alter the metabolic fate of fluoropyrimidines, leading to possible alterations in drug efficacy or toxicity. The specific mechanism of action of DPYD inhibitors may involve competitive binding to the active site of the enzyme or inducing structural changes that interfere with its catalytic function. The study of DPYD inhibitors has been instrumental in understanding the complex interplay between DPD and fluoropyrimidine drugs, providing valuable insights into drug metabolism. Continued research in this area may lead to further advancements in drug development and personalized medicine, with a focus on maximizing drug efficacy and minimizing adverse effects.